Comparative Pharmacology
Head-to-head clinical analysis: TRIPLE SULFOID versus UROPLUS SS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRIPLE SULFOID versus UROPLUS SS.
TRIPLE SULFOID vs UROPLUS SS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Triple sulfoid (sulfadiazine, sulfamethazine, sulfamerazine) competes with para-aminobenzoic acid (PABA) to inhibit dihydropteroate synthase, blocking bacterial folate synthesis.
Uroplus SS contains sulfamethoxazole and trimethoprim. Sulfamethoxazole inhibits bacterial dihydrofolic acid synthesis by competing with para-aminobenzoic acid (PABA) for dihydropteroate synthase. Trimethoprim inhibits bacterial dihydrofolate reductase, blocking reduction of dihydrofolate to tetrahydrofolate. The sequential blockade of folic acid metabolism produces bactericidal activity.
2 tablets orally every 6 hours for 10-14 days; each tablet contains sulfadiazine 270 mg, sulfamerazine 270 mg, and sulfamethazine 270 mg.
4 grams orally once daily as a single dose or in divided doses for 10 to 14 days for urinary tract infections.
None Documented
None Documented
10-12 hours in normal renal function; prolonged to 24-48 hours in severe renal impairment (CrCl <30 mL/min)
Terminal elimination half-life is 18–24 hours, allowing once-daily dosing; steady-state achieved in 3–5 days.
Renal: ~70% as unchanged drug; hepatic metabolism: ~20%; fecal: ~10%
Renal: 70–80% as unchanged drug; fecal: 10–20% via biliary elimination; minimal hepatic metabolism.
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic